Skip to main content

Advertisement

Table 1 Parasite load reduction (percentage) of each drug within 24 h after the first day of treatment with the trioxaquine, artesunate, 4,7-dichloroquinoline and quinine against Plasmodium berghei ANKA in C57BL/6 mice using the established infection test

From: Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model

Drug/dosage (mg/kg) Day 8 pi mean parasitaemia ± SD 24 h post-treatment parasitaemia ± SD 48 h post-treatment parasitaemia ± SD Percentage parasitaemia clearance in 24 h Recrudescence
Trioxaquine
 25 11.73 ± 0.06 0.42 ± 0.11 0.00 96.4 Not observed
 12.5 11.69 ± 0.03 1.56 ± 0.08 0.00 86.6 Not observed
Artesunate
 12.5 11.75 ± 0.05 1.77 ± 0.04 0.00 84.8 Observed
4,7-Dichloroquinoline
 12.5 11.55 ± 0.07 11.45 ± 0.04 11.41 ± 0.02 1.89 ND
Quinine
 60 11.65 ± 0.03 11.79 ± 0.01 6.52 ± 0.02 1.03 Observed
Untreated control 11.67 ± 0.05 11.83 ± 0.04 100% Mortality recorded
  1. Treatment was initiated on day 8 post-infection. Drugs administered iv twice a day, for 3 days, within 12-h intervals and parasitaemia data before and 24 h post-treatment compared using paired Student t test (p < 0.05). Parasitaemia levels were similar in all the experimental groups before treatment (ANOVA, p >0.05)
  2. ND not determined (100% mortality occurred)